NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
46.99
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-3.41 Insider Own3.19% Shs Outstand74.99M Perf Week0.04%
Market Cap3.54B Forward P/E- EPS next Y-0.92 Insider Trans-15.90% Shs Float72.94M Perf Month0.66%
Enterprise Value3.26B PEG- EPS next Q-0.74 Inst Own97.89% Short Float8.75% Perf Quarter-0.89%
Income-253.93M P/S16.12 EPS this Y23.89% Inst Trans-19.81% Short Ratio1.11 Perf Half Y27.66%
Sales219.67M P/B8.44 EPS next Y65.27% ROA-43.70% Short Interest6.38M Perf YTD30.06%
Book/sh5.57 P/C12.30 EPS next 5Y- ROE-51.57% 52W High62.00 -24.21% Perf Year29.73%
Cash/sh3.82 P/FCF- EPS past 3/5Y0.98% -24.25% ROIC-60.02% 52W Low28.21 66.57% Perf 3Y83.55%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin91.48% Volatility0.06% 0.18% Perf 5Y5.67%
Dividend TTM- EV/Sales14.84 EPS Y/Y TTM31.63% Oper. Margin-120.52% ATR (14)0.20 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.18 Sales Y/Y TTM730.42% Profit Margin-115.60% RSI (14)63.70 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio4.33 EPS Q/Q6.22% SMA200.32% Beta0.70 Target Price47.00
Payout- Debt/Eq0.02 Sales Q/Q133.68% SMA502.41% Rel Volume0.00 Prev Close46.99
Employees368 LT Debt/Eq0.01 EarningsMay 01 SMA20014.07% Avg Volume5.74M Price46.99
IPOSep 13, 2019 Option/ShortYes / No EPS/Sales Surpr.-16.87% -13.19% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-20-24Initiated Evercore ISI Outperform $60
Feb-05-24Initiated Guggenheim Buy $75
Dec-01-22Initiated BofA Securities Buy $45
Jan-19-21Reiterated H.C. Wainwright Buy $87 → $101
Oct-29-20Reiterated H.C. Wainwright Buy $58 → $73
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Jul-02-25 07:03AM
Jul-01-25 08:30AM
Jun-24-25 12:45PM
Jun-20-25 08:00AM
May-27-25 09:25AM
11:25AM Loading…
May-26-25 11:25AM
May-23-25 08:00AM
May-09-25 05:40PM
May-06-25 08:50AM
May-01-25 12:15PM
Apr-29-25 03:46PM
09:55AM
Apr-28-25 10:35AM
09:33AM
07:37AM
06:47AM Loading…
06:47AM
02:13AM
02:11AM
Apr-27-25 10:35AM
Apr-25-25 08:09AM
Apr-24-25 06:51PM
Apr-20-25 11:28AM
Mar-01-25 02:41PM
Feb-23-25 03:17PM
Feb-20-25 09:01AM
06:30AM
Feb-19-25 08:00AM
Feb-18-25 05:38AM
Feb-13-25 11:05AM
11:00AM
10:50AM Loading…
10:50AM
Feb-11-25 08:20PM
05:27PM
02:07AM
Jan-30-25 07:00AM
Jan-13-25 02:47PM
06:30AM
Jan-09-25 08:40AM
Jan-08-25 02:54PM
07:26AM
Jan-03-25 06:30AM
Nov-26-24 07:00AM
Nov-14-24 08:00AM
Nov-13-24 02:10AM
Nov-12-24 09:25AM
06:43AM
06:30AM
Nov-11-24 07:08AM
07:00AM
06:30AM
Nov-07-24 06:30AM
Nov-05-24 07:00AM
Oct-22-24 07:00AM
Oct-09-24 05:12PM
Sep-04-24 07:00PM
Aug-28-24 06:30AM
Aug-07-24 06:30AM
Jul-29-24 06:30AM
Jul-23-24 07:00AM
Jul-12-24 11:27AM
Jul-02-24 12:12PM
Jul-01-24 06:30AM
Jun-06-24 02:34AM
02:34AM
02:34AM
Jun-05-24 07:00AM
May-23-24 05:13PM
May-08-24 07:00AM
May-03-24 03:18AM
May-02-24 10:53AM
07:45AM
06:30AM
Apr-24-24 01:31PM
Apr-18-24 07:00AM
Mar-04-24 06:30AM
Feb-29-24 08:30AM
Feb-27-24 07:12AM
06:30AM
Feb-22-24 07:00AM
Feb-07-24 02:42AM
Feb-05-24 11:26PM
Jan-31-24 07:00AM
Jan-08-24 06:30AM
Dec-21-23 07:00AM
Dec-08-23 04:05PM
Dec-05-23 12:32AM
Dec-04-23 04:13PM
Nov-29-23 07:00AM
Nov-28-23 04:41PM
04:03PM
Nov-27-23 06:04PM
Nov-16-23 06:30AM
Nov-02-23 07:54AM
06:30AM
Nov-01-23 06:30AM
Sep-11-23 06:30AM
Aug-02-23 06:30AM
Jun-28-23 08:29PM
Jun-07-23 07:00AM
Jun-05-23 06:30AM
SpringWorks Therapeutics focuses on developing and commercializing innovative therapies for cancer treatment. The company specializes in targeted oncology, aiming to provide solutions that address unmet medical needs in the oncology space. SpringWorks offers a range of therapies, including those that target specific genetic mutations in tumors. Their research emphasizes precision medicine, utilizing advanced methodologies to enhance treatment efficacy. The company engages in collaborations to accelerate the development of its pipeline and improve patient outcomes in oncology.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Edris BadreddinChief Operating OfficerMar 03 '25Sale54.2320,0001,084,592169,712Mar 05 06:33 PM
Islam SaqibChief Executive OfficerMar 03 '25Sale54.2449,0002,657,656954,869Mar 05 06:32 PM
Islam SaqibChief Executive OfficerFeb 20 '25Sale60.3029,3281,768,4011,034,625Feb 24 06:58 PM
Ashar BhaveshChief Commercial OfficerFeb 20 '25Sale61.191,01662,16862,053Feb 24 06:58 PM
LYNCH DANIELDirectorFeb 20 '25Sale60.2247,6002,866,53482,944Feb 24 06:57 PM
Bhavesh AsharOfficerFeb 20 '25Proposed Sale61.3816,090987,604Feb 20 04:18 PM
Islam SaqibChief Executive OfficerFeb 14 '25Sale59.9210,672639,4901,063,953Feb 19 04:50 PM
LYNCH DANIELDirectorFeb 14 '25Sale60.0040024,000130,544Feb 19 04:49 PM
DANIEL LYNCHDirectorFeb 14 '25Proposed Sale58.5948,0002,812,320Feb 14 04:21 PM
Pichl DanielChief People OfficerFeb 10 '25Option Exercise27.6429,750822,29080,512Feb 12 08:01 PM
Pichl DanielChief People OfficerFeb 10 '25Sale54.3629,7501,617,32950,762Feb 12 08:01 PM
LYNCH DANIELDirectorFeb 10 '25Sale54.46175,0009,530,351130,944Feb 12 07:59 PM
Islam SaqibChief Executive OfficerFeb 10 '25Sale53.3048,0002,558,2371,002,502Feb 12 07:58 PM
Hambleton JulieDirectorFeb 10 '25Option Exercise32.2713,774444,48717,869Feb 12 07:57 PM
Hambleton JulieDirectorFeb 10 '25Sale53.0113,774730,2074,095Feb 12 07:57 PM
Edris BadreddinChief Operating OfficerFeb 10 '25Sale53.1330,0001,593,795189,712Feb 12 07:55 PM
Saqib IslamOfficerFeb 10 '25Proposed Sale53.30137,0007,301,552Feb 10 04:38 PM
DANIEL LYNCHDirectorFeb 10 '25Proposed Sale40.28175,0007,049,000Feb 10 04:29 PM
Daniel PichlOfficerFeb 10 '25Proposed Sale54.3629,7501,617,329Feb 10 04:13 PM
Julie HambletonBoard MemberFeb 10 '25Proposed Sale53.0113,774730,207Feb 10 04:09 PM
Badreddin EdrisOfficerFeb 10 '25Proposed Sale41.0050,0002,050,000Feb 10 04:08 PM
Edris BadreddinChief Operating OfficerDec 03 '24Sale41.9720,000839,336209,600Dec 05 06:14 PM
Islam SaqibChief Executive OfficerDec 02 '24Sale41.3749,0002,027,3571,014,368Dec 04 04:23 PM
Islam SaqibChief Executive OfficerSep 03 '24Sale40.5749,0001,988,0331,063,368Sep 04 04:05 PM
Edris BadreddinChief Operating OfficerSep 03 '24Sale40.6520,000812,954229,600Sep 04 04:05 PM
Badreddin EdrisOfficerSep 03 '24Proposed Sale41.7850,0002,089,000Sep 03 04:09 PM
Saqib IslamOfficerSep 03 '24Proposed Sale41.58146,0006,070,680Sep 03 04:07 PM